explore -WSS

explore

author：knowledge 2025-10-01 07:41:58 - browse：2

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

WSS

A new study asks: Are we harming blood donors by taking blood?

Listen: PBM conflicts, RSV vaccines, & the future of flu season

What is STAT's opinion section for?

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Did the public have the right to know Arthur Ashe had AIDS?

Today's health inequities arise from racist U.S. history, say experts

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Supreme Court strikes down use of affirmative action

Grail is spending more than ever lobbying Congress

New air purifier tech could be key to improving indoor air quality

White House drug czar issues call for 'recovery

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

7 people shot in DC, police say

New air purifier tech could be key to improving indoor air quality

Make 'food is medicine' a key part of White House nutrition meeting

How to save PrEP access — and even expand it

NIH chief: government has fallen behind pharma on clinical trials

hotspot

Did the public have the right to know Arthur Ashe had AIDS?

Ohio still needs to do more to protect the right to abortion

7 people shot in DC, police say

Grail is spending more than ever lobbying Congress

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Connecting traumatic brain injury and domestic violence

focus

entertainment

explore

focus